CMS Mandates GLOBE Pricing Model for Medicare Part B Drugs
What happened
The Centers for Medicare & Medicaid Services published the final rule for the Global Benchmark for Efficient Drug Pricing (GLOBE) Model on October 2, 2026. GLOBE is a mandatory Medicare Part B most-favored-nation (MFN) pricing model that uses international pricing benchmarks to calculate manufacturer rebates for qualifying drugs. The rule applies to specific single-source drugs and sole-source biological products in specified therapeutic categories, while also narrowing product eligibility.
From natlawreview.com
Why it matters
The rule establishes a new pricing structure for drugs covered under Medicare Part B. Manufacturers must now base their rebate calculations on international pricing benchmarks, which impacts their commercial agreements and supply planning. This regulatory shift directly affects the cost structure of pharmaceuticals within the federal health insurance program.
CMS manages the federal health insurance program and handles adjustments for Medicare Part B.
From natlawreview.com
Who's involved
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- UnitedHealth GroupSpeculative
UnitedHealth Group might face increased claims costs due to regulatory changes in drug pricing.
- Bristol-Myers SquibbSpeculative
Bristol-Myers Squibb may have its drug rebate calculations altered by the mandatory MFN pricing model.
- Eli Lilly and CompanySpeculative
Eli Lilly and Company could see pricing and rebate calculations mandated by international benchmarks.
- AstraZenecaSpeculative
AstraZeneca might have its drug rebate calculations altered by the mandatory MFN pricing model.
- HumanaSpeculative
Humana may face increased claims costs due to regulatory changes in drug pricing.